Eli Lilly launched its oral obesity pill Foundayo, entering direct competition with Novo Nordisk’s oral Wegovy and intensifying the pricing-and-access push in the rapidly expanding GLP-1 category. Lilly said the lowest dose is available beginning at $149 per month for self-pay patients, and it highlighted co-pay support options and insurance affordability mechanisms. The launch follows FDA approval last week and positions Foundayo to leverage Medicare coverage expansion starting July 1. Lilly also emphasized dosing convenience relative to oral Wegovy’s administration constraints. The market impact hinges on adoption curves, reimbursement and Medicare rules, and patient preference between different pill regimens. Both companies are also navigating tariff-related pricing negotiations that could affect net price dynamics. For biopharma executives, the event reflects how oral formulations are shifting competitive strategy from device and injection logistics toward oral adherence, access partnerships, and payer economics.